NCT04682353View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

July 11, 2022

Study Completion Date

January 12, 2023

Conditions
Contraception
Interventions
DRUG

TV-46046

SC injection of 300 mg/mL (120 mg/0.4mL; 180 mg/0.6mL; 240 mg/0.8mL)

DRUG

Depo-subQ Provera

SC injection of 104 mg/0.65 mL

Trial Locations (3)

78209

Teva Investigational Site 14003, San Antonio

90630

Teva Investigational Site 14002, Cypress

99999

Teva Investigational Site 18001, Santo Domingo

All Listed Sponsors
collaborator

FHI 360

OTHER

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT04682353 - A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age | Biotech Hunter | Biotech Hunter